Managing the menopause: British Menopause Society Council consensus statement on hormone replacement therapy

Journal of the British Menopause Society

Volumn 11, Issue 4, 2005, Pages 152-156

  Pitkin, Joan ^a,b   Rees, Margaret C P ^a   Gray, Sarah ^a   Lumsden, Mary Ann ^a   Marsden, Jo ^a   Stevenson, John ^a   Williamson, Jennifer ^a  

^a British Menopause Society   (United Kingdom)

^b ST MARK S HOSPITAL   (United Kingdom)

Author keywords

Estrogen; Hormone replacement therapy; Menopause; Progestogen; Tibolone

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; TIBOLONE;

ALZHEIMER DISEASE; ARTICLE; BREAST CANCER; CLINICAL OBSERVATION; CLINICAL TRIAL; CONSENSUS; DATA ANALYSIS; DEMENTIA; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; ENDOMETRIUM CANCER; FEMALE; GALLBLADDER DISEASE; HEALTH PRACTITIONER; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL SOCIETY; MENOPAUSAL SYNDROME; OVARY CANCER; PATIENT CARE; PATIENT COUNSELING; PRACTICE GUIDELINE; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; STROKE; UNITED KINGDOM; VENOUS THROMBOEMBOLISM;

ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; GREAT BRITAIN; HUMANS; MENOPAUSE; STATE MEDICINE; WOMEN'S HEALTH;

EID: 30844443237     PISSN: 13621807     EISSN: 13621807     Source Type: Journal    
DOI: 10.1258/136218005775544354     Document Type: Article

References (39)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
2. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-54
3. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84
4. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-62
5. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2663-72
6. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative randomized trial. JAMA 2003;289:3243-53
7. Manson JE, Hsia J, Johnson KC, et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34
8. Anderson GL, Judd HL, Kaunitz AM, et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739-48
9. Cauley JA, Robbins J, Chen Z, et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-38
10. Cushman M, Kuller LH, Prentice R, et al. Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80
11. Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005;105:1063-73
12. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
13. Espeland MA, Rapp SR, Shumaker SA, et al. Women's Health Initiative Memory Study. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2959-68
14. Shumaker SA, Legault C, Kuller L, et al. Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947-58
15. Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA 2005;293:330-9
16. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27
17. Beral V, Bull D, Reeves G, Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-51
18. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109
19. Garton M (and others) Breast cancer and hormone-replacement therapy: the Million Women Study. Lancet 2003;362:1328-31
20. Whitehead M, Farmer R. The Million Women Study: a critique. Endocrine 2004;24:187-93
21. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2001;(1):CD002978
22. Cardozo L, Bachmann G, McClish D, et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722-7
23. Floter A, Nathorst-Boos J, Carlstrom K, von Schoultz B. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being. Climacteric 2002;5:357-65
24. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralowdose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004;104:443-51
25. Royal College of Physicians. Osteoporosis: clinical guidelines for prevention and treatment. Update on pharmacological interventions and an alogorithm for management. London: Royal College of Physicians, 2000. See http://www.rcplondon.ac.uk/pubs/wp_osteo_update.htm (last acesseed 23 September 2005)
26. La Vecchia C, Brinton LA, McTiernan A. Cancer risk in menopausal women. Best Pract Res Clin Obstet Gynaecol 2002;16:293-307
27. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-7
28. NHS Breast Screening Review 2002. See http://www.cancer-screening.nhs.uk (last accessed 23 September 2005)
29. The Million Women Study Collaborators. The Million Women Study: design and characteristics of the study population. Breast Cancer Res 1999;1:73-80
30. Greendale GA, Reboussin BA, Sie A, et al., for the Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999;130:262-9
31. Greendale GA, Reboussin BA, Slone S, et al. Postmenopausal hormone therapy and change in mammographic density. Natl Cancer Inst 2003;95:30-7
32. Smith-Bindman R, Chu PW, Miglioretti DL, et al. Comparison of screening mammography in the United States and the United Kingdom. JAMA 2003;290:2129-37
33. Royal College of Obstetricians and Gynaecologists. Hormone Replacement Therapy and Venous Thromboembolism. Green Top Guideline No. 19. London: RCOG, revised January 2004
34. Hoibraaten E, Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy - results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84:961-7
35. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
36. Gabriel SR, Carmona L, Roque M, Sanchez GL, Bonfill X. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2005;(2):CD002229
37. Kesslak JP. Can estrogen play a significant role in the prevention of Alzheimer's disease? J Neural Transm Suppl 2002;62:227-39
38. Zethraeus N, Johannesson M, Henriksson P, Strand RT. The impact of hormone replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol 1997;104:1191-5
39. Swegle JM, Kelly MW. Tibolone: a unique version or hormone replacement therapy. Ann Pharmacother 2004;38:874-81